Saturday, July 11, 2026

Drug profile · INN

gozetotide

gozetotide (LOCAMETZ) is a diagnostic agent.

EMA: approved Various (V09) V09I
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — gozetotide
Class
Various (V09)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

gozetotide (LOCAMETZ) is a diagnostic agent.

Key facts

INN gozetotide
Brand LOCAMETZ
Mechanism Diagnostic agent
Therapeutic class Various (V09)
ATC code V09I

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. 115747 Phase 3 · Disc Medicine · Metastatic renal cell carcinoma
  2. PBP-301 Phase 3 · Anaxis Pharma · Metastatic castration-resistant prostate cancer (mCRPC)
  3. CAMO959A12103 Phase 2 · Novartis India · PSMA-positive mCRPC with prior exposure to at least one prio
  4. CJSB462B12201 Phase 2 · Novartis India · Metastatic castration resistant prostate cancer (mCRPC)
  5. Gallium Ga 68 Gozetotide Phase 2 · United Therapeutics Europe · Hepatocellular Carcinoma

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. sugammadex sodium Various (V03)

Frequently asked questions

What is gozetotide?

gozetotide (LOCAMETZ) is a diagnostic agent.

What is the brand name for gozetotide?

LOCAMETZ is a marketed brand name for gozetotide. Check FDA Drugs@FDA for the current US label holder and prescribing information.